SEC Form 4 · accession 0001437749-18-003793
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark R. Klausner
Director
Period of report
Mar 1, 2018
Accepted (ET)
Mar 2, 2018 · 4:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHARE OPTION (RIGHT TO BUY)F1 | $10.93 | Mar 1, 2018 | A | 3,728 | A | — | Mar 1, 2028 | ORDINARY SHARES | 3,728 | 3,728 | D |
| SHARE OPTION (RIGHT TO BUY)F2 | $10.93 | Mar 1, 2018 | A | 14,914 | A | — | Mar 1, 2028 | ORDINARY SHARES | 14,914 | 14,914 | D |
Explanation of responses
- F1This option will vest and become exercisable as to 100% of the underlying shares on the date of the first annual meeting of the issuer's shareholders held after the date of grant.
- F2This option will vest and become exercisable as to one-third of the shares on each date on which the first three annual meetings of the issuer's shareholders are held after the date of grant.